Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Vitamin C Supplements Tied to Fewer Deaths in Blood Disorder Trial (opens in a new tab)

scitechdaily.com · 2026-09-25

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Four of six claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 4 supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredAfter a median follow-up of 33.6 months, there were 35 deaths in total, with 24 in the placebo group and 11 in the vitamin C group.View evidenceHide evidence

As stated35 deaths total; 24 placebo, 11 vitamin C; median follow-up 33.6 months

Why this verdict

The abstract-level profile supports an exploratory overall-survival difference and reports an HR, CI, and p-value, but it explicitly notes that follow-up duration and survival event counts are not provided in the abstract. The specific median follow-up of 33.6 months and death counts of 24 versus 11 cannot be verified from the supplied abstract-depth profile.

1

Study evidence

In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025

“followed by long-term follow-up”
Claim 2 of 6Not coveredParticipants taking vitamin C showed changes in inflammatory signaling consistent with better outcomes, and several problems were less frequent, including anemia, pneumonia, internal bleeding, and acute aseptic arthritis, while gastrointestinal problems were more common.View evidenceHide evidence

Why this verdict

The abstract profile supports only broad secondary findings: differences in inflammatory cytokine trajectories and fewer serious adverse events in the vitamin C arm. It does not provide the direction, magnitude, or specific cytokines, and it does not verify the specific adverse-event categories listed by the story, such as anemia, pneumonia, internal bleeding, acute aseptic arthritis, or more gastrointestinal problems. Those details may be in the full paper, but they are not verifiable at abstract depth.

1

Study evidence

Fewer serious adverse events (SAEs) occurred in the vitamin C arm than in the placebo arm during the 12-month treatment period.18 of 55 (33%) in VitC vs 30 of 53 (57%) in placebo (as reported in abstract)

“secondary outcomes included ... fewer serious adverse events in the VitC group versus placebo (18 of 55 [33%] vs. 30 of 53 [57%]).”
2

Study evidence

Secondary outcomes reported differences in inflammatory cytokine trajectories between the vitamin C and placebo arms over the trial period.

“secondary outcomes included differences in inflammatory cytokine trajectories”
Claim 3 of 6SupportedA phase 2 trial linked vitamin C supplements to better survival in people with certain blood disorders, and the finding requires further study in a larger phase 3 trial.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that EVITA was a phase 2 randomized trial and that exploratory long-term follow-up found longer overall survival with vitamin C versus placebo. It also supports the need for confirmation in a phase 3 trial. The claim is appropriately hedged as a link and notes further study, so the headline does not outrun the paper evidence.

1

Study evidence

In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025

“followed by long-term follow-up”
Claim 4 of 6SupportedVitamin C supplements were linked to better survival in a clinical trial involving people with precancerous blood conditions or low-risk blood cancers.View evidenceHide evidence

Why this verdict

The paper profile supports that adults with CCUS or lower-risk myeloid malignancies were randomized in EVITA and that exploratory analyses reported longer overall survival with vitamin C. The story frames this as an association/link in a clinical trial rather than a definitive survival benefit.

1

Study evidence

In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025

“followed by long-term follow-up”
2

Study evidence

Twelve months of oral vitamin C (1000 mg/day) did not alter the median clonal growth rate compared with placebo in adults with CCUS or lower-risk myeloid malignancies.-0.016 (95% CI, -0.096 to 0.064); p = 0.70

“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
Claim 5 of 6SupportedThe trial’s main measure, growth rate of precancerous or cancerous cells, was similar between participants taking vitamin C and those receiving placebo.View evidenceHide evidence

Why this verdict

The abstract profile states that the prespecified primary endpoint was median clonal growth rate from baseline to end of treatment and that it did not differ between the vitamin C and placebo groups.

1

Study evidence

Twelve months of oral vitamin C (1000 mg/day) did not alter the median clonal growth rate compared with placebo in adults with CCUS or lower-risk myeloid malignancies.-0.016 (95% CI, -0.096 to 0.064); p = 0.70

“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
Claim 6 of 6SupportedIn the EVITA trial, 109 patients were randomly assigned to 1,000 milligrams of oral vitamin C daily or placebo for 12 months in a double-blind phase 2 study.View evidenceHide evidence

As stated109 patients; 55 vitamin C, 54 placebo; 1,000 mg daily; 12 months

Why this verdict

The abstract profile supports the design and dosing details: EVITA was a double-blind randomized placebo-controlled phase 2 trial; 109 adults were enrolled, with 55 assigned to vitamin C and 54 to placebo; participants received oral vitamin C 1000 mg/day or placebo for 12 months.

1

Study evidence

Twelve months of oral vitamin C (1000 mg/day) did not alter the median clonal growth rate compared with placebo in adults with CCUS or lower-risk myeloid malignancies.-0.016 (95% CI, -0.096 to 0.064); p = 0.70

“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • At abstract depth, the survival profile does not provide follow-up duration, death/event counts, censoring patterns, or survival-model details.

    The story gives specific follow-up and death counts, but those details are not present in the supplied abstract-depth paper profile. The story caveats mention exploratory status and phase 3 confirmation, but not the absence of these survival-analysis details at this evidence depth.

    From Double-blind, randomized, placebo-controlled phase 2 trial with long-term follow-up and exploratory time-to-event (overa

  • Secondary biomarker results included differences in inflammatory cytokine trajectories, but the abstract does not report specific cytokines, direction, magnitude, p-values, assay details, or multiplicity handling.

    The story says inflammatory signaling changes were consistent with better outcomes, but the supplied profile only supports unspecified differences in cytokine trajectories and highlights missing details that limit interpretation.

    From Randomized, double-blind, placebo-controlled phase 2 trial

4 things the story did carry across
  • EVITA was a randomized, double-blind, placebo-controlled phase 2 trial in adults with CCUS or lower-risk myeloid malignancies, testing oral vitamin C 1000 mg/day versus placebo for 12 months.
  • The prespecified primary endpoint was median clonal growth rate from baseline to end of treatment, and it did not differ between groups.
  • Overall survival was longer with vitamin C in exploratory analyses, not as the primary endpoint, and the authors state that a phase 3 trial is warranted.
  • Safety/tolerability was a secondary outcome; the abstract reports fewer serious adverse events in the vitamin C arm than placebo.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate whether 12 months of oral vitamin C vs placebo alters clonal dynamics (clonal growth rate) in adults with CCUS or lower-risk myeloid malignancies.Phase 2 randomized double-blind placebo-controlled trialExpand

In plain English

Phase 2 double-blind randomized placebo-controlled trial (EVITA) testing whether 12 months of oral vitamin C (1000 mg/day) versus placebo alters clonal dynamics (median clonal growth rate) in adults with CCUS or lower-risk myeloid malignancies not receiving anticancer therapy. The primary endpoint (median clonal growth rate from baseline to end of 12-month treatment) did not differ between groups.

Key findings

  • Twelve months of oral vitamin C (1000 mg/day) did not alter the median clonal growth rate compared with placebo in adults with CCUS or lower-risk myeloid malignancies.-0.016 (95% CI, -0.096 to 0.064); p = 0.70
“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
What this piece can’t prove
  • Phase 2 trial; authors state a phase 3 trial is warranted to confirm findings.
2human in vivoAssess safety/tolerability of oral vitamin C vs placebo (including serious adverse events).Double-blind randomized placebo-controlled phase 2 trialExpand

In plain English

EVITA was a double-blind, randomized, placebo-controlled phase 2 trial comparing oral vitamin C (1000 mg/day) versus placebo for 12 months in adults with CCUS or lower-risk myeloid malignancies not receiving anticancer therapy. Safety/tolerability outcomes reported in the abstract indicate fewer serious adverse events (SAEs) in the vitamin C arm than placebo during the treatment period.

Key findings

  • Fewer serious adverse events (SAEs) occurred in the vitamin C arm than in the placebo arm during the 12-month treatment period.18 of 55 (33%) in VitC vs 30 of 53 (57%) in placebo (as reported in abstract)
“secondary outcomes included ... fewer serious adverse events in the VitC group versus placebo (18 of 55 [33%] vs. 30 of 53 [57%]).”
What this piece can’t prove
  • Abstract-only report: limited methodological detail on adverse event collection, definitions, and adjudication.
  • Relatively small sample size for safety endpoints (phase 2), limiting precision of effect estimates for harms.
  • Potential differences in follow-up or censoring between arms not described in abstract.

1 further detail could not be confirmed from the summary.

3human in vivoAssess biological activity signals of vitamin C vs placebo, including inflammatory cytokine trajectories.Randomized, double-blind, placebo-controlled phase 2 trialExpand

In plain English

In the EVITA randomized, double-blind, placebo-controlled phase 2 trial (oral vitamin C 1000 mg/day vs placebo for 12 months, n=109), the abstract reports secondary outcome differences in inflammatory cytokine trajectories between the vitamin C and placebo arms, interpreted as a biological activity signal. The abstract does not report which cytokines, the direction or magnitude of changes, or statistical estimates for these biomarker trajectories.

Key findings

  • Secondary outcomes reported differences in inflammatory cytokine trajectories between the vitamin C and placebo arms over the trial period.
“secondary outcomes included differences in inflammatory cytokine trajectories”
What this piece can’t prove
  • As a secondary outcome, the cytokine results may be exploratory; the abstract does not state whether these analyses were pre-specified or adjusted for multiple comparisons.

2 further details could not be confirmed from the summary.

4human in vivoExplore longer-term clinical outcomes after treatment, including overall survival, during follow-up.Double-blind, randomized, placebo-controlled phase 2 trial with long-term follow-up and exploratory time-to-event (overall survival) analysisExpand

In plain English

Exploratory long-term follow-up of the randomized, double-blind, placebo-controlled EVITA phase 2 trial (n=109) reports a longer overall survival with oral vitamin C (1000 mg/day for 12 months) versus placebo (exploratory HR 0.35; 95% CI 0.17–0.71; p = .0025). The analysis is labeled exploratory in the abstract; details on follow-up duration, censoring, and modeling are not provided there.

Key findings

  • In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025
  • The primary trial endpoint, median clonal growth rate from baseline to end of treatment, showed no difference between vitamin C and placebo.-0.016 (95% CI -0.096 to 0.064); p = .70
“followed by long-term follow-up”
What this piece can’t prove
  • Abstract does not report follow-up duration, number of events, censoring patterns, or details of the survival model.
  • Phase 2 trial with relatively small randomized sample (n=109); event counts and power for survival differences not provided in abstract.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 35 candidate papers

SelectedOpen access

Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial.

Cancer · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

SAT-332 Antibiotic therapy, not disease severity, shapes the intestinal and oral microbiomes in acutely decompensated cirrhosis

Journal of Hepatology · 2026 · Crossref

Source (opens in a new tab)
Candidate

Catalysing the green transition through collaborative innovation: A longitudinal study of green diplomacy in strategic partnerships between Denmark and China

Asian Business & Management · 2026 · Crossref

Source (opens in a new tab)

And 29 more candidates considered.